Live Breaking News & Updates on Vivo Capital|Page 4

Stay updated with breaking news from Vivo capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

enGene Holdings Inc. (NASDAQ:ENGN) Receives $34.40 Consensus Target Price from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have earned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock […] ....

Leerink Partnrs , Altitude Crest Partners Inc , Omega Fund Management , Morgan Stanley , Janus Henderson Group , Vivo Capital , Dgene Inc , Gene Company Profile , Gene Holdings Inc , Gene Holdings , Get Free Report , Crest Partners , Henderson Group , Fund Management , Gene Stock Down , Gene Company , Get Free , Bacillus Calmette Gu , Gene Daily ,

enGene (NASDAQ:ENGN) Stock Price Down 5.7%

enGene (NASDAQ:ENGN) Stock Price Down 5.7%
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Leerink Partnrs , Janus Henderson Group , Dgene Inc , Gene Holdings Inc , Omega Fund Management , Vivo Capital , Wells Fargo Company , Altitude Crest Partners Inc , Morgan Stanley , Gene Holdings , Get Free Report , Wells Fargo , Gene Price , Crest Partners , Henderson Group , Fund Management , Bacillus Calmette Gu , Gene Daily ,

Silence Therapeutics (NASDAQ:SLN) Earns "Buy" Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $42.00 price target on the stock. A number of other analysts have also commented on SLN. BMO Capital Markets initiated coverage on Silence Therapeutics […] ....

Janus Henderson Group , Vivo Capital , Parkman Healthcare Partners , Morgan Stanley , Sg Americas Securities , Chardan Capital , Silence Therapeutics , Free Report , Get Free Report , Healthcare Partners , Oligonucleotide Discovery , Silence Therapeutics Daily ,

Delcath Systems, Inc. (NASDAQ:DCTH) Receives $18.50 Average Target Price from Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) have earned an average rating of “Buy” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued ratings on the […] ....

United States , Gil Aharon , Vanguard Group Inc , Securities Exchange Commission , Vivo Capital , Capital Management , Delcath Systems Inc , Delcath Systems , Get Free Report , Marketbeat Ratings , Director Gil Aharon , Exchange Commission , Get Free , Delcath Systems Daily ,